14 results about "Semaglutide" patented technology

The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway. As a marketed drug, semaglutide has clear safety, a long half-life and high patient compliance, and has a significant clinical conversion prospect. The application breaks through the limitation that existing hormone replacement therapy and assisted reproductive technology can only treat symptoms or solve the problem of fertility, provides a first drug intervention strategy which can fundamentally delay the process of follicle depletion, and fills the blank in the field of ovarian aging treatment.

The application belongs to the technical field of hydrogel preparation, and particularly relates to a hydrogel loaded with semaglutide and a preparation method and application thereof. The preparation method comprises the following steps: adding ferulic acid modified chitosan into deionized water to obtain a modified chitosan solution, adding oxidized dextran into deionized water, ultrasonic dissolving to obtain an oxidized dextran solution, adding semaglutide into the oxidized dextran solution to obtain an oxidized dextran mixed solution, and mixing the modified chitosan solution and the oxidized dextran mixed solution to obtain the hydrogel loaded with semaglutide. The hydrogel loaded with semaglutide has the advantages of short gelation time, good injection performance, non-toxicity and good biocompatibility. The hydrogel can significantly reduce myocardial interstitial fibrosis after myocardial infarction and improve the ejection capacity of the heart after myocardial infarction. The hydrogel can be used for preparing drugs for treating myocardial infarction.

The objective invention provides a parenteral composition of semaglutide or a pharmaceutically acceptable salt thereof for subcutaneous administration, having a strength and composition such that it can be administered multiple times from single article of manufacture, for use in treating type 2 diabetes mellitus and for weight loss, thereby providing benefit to the patient.

The present disclosure provides formulations, methods and implantable devices that improve patient compliance by releasing a desired therapeutic agent such as semaglutide for a long time period, such as 1 year or more. The semaglutide concentration (w / w) is more than 1%, such as about 1.1% w / w to about 35% w / w.

Disclosed is a sustained-release formulation of semaglutide, which comprises semaglutide or a pharmaceutically acceptable salt thereof, triacylglycerol, phosphatidylcholine, absolute ethyl alcohol, a solubilizing agent, and a pH adjusting agent.

Disclosed is a sustained-release formulation of semaglutide. The sustained-release formulation of semaglutide comprises semaglutide or a pharmaceutically acceptable salt thereof, triacylglycerol, phosphatidylcholine, absolute ethanol, a solubilizer, and a pH regulator.

The present invention provides a pharmaceutical composition comprising semaglutide or a salt thereof, a bioavailability improver, and sustained-release microspheres made of a biodegradable polymer, exhibiting high bioavailability and stable drug release characteristics over a long period of time, and a pharmaceutical composition comprising semaglutide or a salt thereof and sustained-release microspheres made of a biodegradable polymer, exhibiting safe drug release characteristics with high drug content and low initial release, and a method for producing the sustained-release microspheres. [Solution] A pharmaceutical composition for the prevention or treatment of diabetes, type 2 diabetes, preservation of beta-cell function, obesity, non-alcoholic steatohepatitis, and degenerative neurological diseases, comprising semaglutide or a salt thereof, a bioavailability improving agent, and a biodegradable polymer-based sustained-release microglobules, wherein the semaglutide or a salt thereof is present in an amount of 8% by weight or more of semaglutide relative to the total weight of the microglobules, and the bioavailability improving agent is present in an amount of 2.5% to 250% by weight relative to the weight of semaglutide, and a method for producing the same.

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

Disclosed herein are compositions and constructs related to a polypeptide, PT-X'n-PTA-Hm (1 ), or pharmaceutically acceptable salts thereof, wherein PT is a peptide transport or fragment thereof; X'n is linker comprising a triazole moiety, n = 0 or 1; PTA is a peptide therapeutic agent selected from the group consisting of a modified semaglutide, a modified tirzepatide, caplacizumab, ozoralizumab; and Hm is a histidine tag where m is 0 to 6; as well as uses thereof.

This invention belongs to the field of peptide drug synthesis, specifically relating to a method for synthesizing smegglutinin. This method uses a modified amino resin as the solid-phase resin, which can significantly improve the yield and purity of the peptide, and the raw materials are inexpensive and the method is simple.

This invention discloses a side-chain modified semaglutide, specifically relating to biomedicine, with the structural formula of HOOC-(CH2). n -His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-O-S-S-CPP, where n is 2-20; This invention enhances the membrane permeability of smegglutinin by modifying its chemical structure, enabling its application in oral spray administration, reducing patient discomfort while maintaining good efficacy.

The present application relates to a soluble microneedle patch of semaglutide and a preparation method and use thereof. The soluble microneedle patch of semaglutide comprises a drug-loaded needle tip layer and a back plate layer; the drug-loaded needle tip layer comprises semaglutide and a needle tip layer matrix material; the weight percentage of the semaglutide is 85% to 92% and the weight percentage of the needle tip layer matrix material is 8% to 15% based on the total weight of the drug-loaded needle tip layer being 100%; and the needle tip layer matrix material is hyaluronic acid or a salt thereof. The soluble microneedle patch of semaglutide has excellent needle type, superior mechanical strength and skin puncture performance, high safety, fast drug release and penetration rate, and excellent drug utilization rate and bioavailability; the preparation method is simple, controllable, and suitable for large-scale production. In addition, the soluble microneedle patch of semaglutide is convenient and quick to administer, has high patient compliance, and has a broad clinical application prospect.

The invention relates to semaglutide for use in treatment of obesity or overweight of a human subject, wherein said semaglutide is administered subcutaneously in an amount of 7.2 mg per week and is no

The present application relates to the technical field of semaglutide synthesis, and specifically discloses a liquid-phase synthesis method for a side chain of semaglutide. The present application uses simple and low-cost mono-tert-butyl octadecanedioate as a starting material, provides a complete liquid-phase synthesis path for the side chain of semaglutide, and through cooperation of specific condensation reagents and activation reagents, proposes a reusable means for the activation reagent in the synthesis path for the first time. The starting material needs to be added only once, and can be reused 1 to 2 times. The intermediate purification steps in the reaction are few, the production cost can be greatly saved, the production operation is simplified, the product yield and purity are ensured, and each step in the synthesis path of the present application can be controlled within a short time, thereby greatly improving the production efficiency. The reaction conditions can be suitable for standard temperature, are more mild, the process operation is more simple and easy to control, the production cost is lower, and the present application can be suitable for large-scale production.